You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 5, 2024

Claims for Patent: 9,616,104

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,616,104

Title:	Method for treating osteoarthritis using dominant negative tissue necrosis factor
Abstract:	Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro.RTM.-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation.
Inventor(s):	Binette; Francois (San Francisco, CA)
Assignee:	Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:	14/744,941
Patent Claims:	1. A method of inhibiting a proinflammatory agent in a patient having osteoarthritis, the method comprising administering 0.25 mg/kg to 20 mg/kg of XPro.RTM.-1595 in a drug depot to a target tissue site at or near the joint, wherein the proinflammatory agent comprises MMP-3, nitrous oxide, IL-1 or combinations thereof and the drug depot comprises poly (lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) having a molar ratio of 4:1 and the XPro.RTM.-1595 is administered by a continuous infusion over 24 to 48 hours or the XPro.RTM.-1595 is released over at least 3 days to 6 months. 2. A method according to claim 1, wherein the drug depot releases the XPro.RTM.-1595 over a period of at least 24 hours. 3. A method according to claim 1, wherein the XPro.RTM.-1595 is administered before, after or with etanercept, onercept, adalimumab, anakinra, infliximab, autologous blood-derived products, or a combination thereof. 4. A method according to claim 1, wherein the drug depot further comprises polylactide (PLA), polyglycolide (PGA), D-lactide, D,L-lactide, L-lactide, D,L-lactide-caprolactone, D,L-lactide-glycolide-caprolactone or a combination thereof. 5. A method according to claim 1, wherein the XPro.RTM.-1595 is administered before, after or with etanercept, adalimumab, anakinra, infliximab or a combination thereof.

Details for Patent 9,616,104

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2031-01-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2031-01-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2031-01-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2031-01-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2031-01-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.